Insights into the impact of microbiota in the treatment of nafld/nash and its potential as a biomarker for prognosis and diagnosis

Vista sencilla de ítem
dc.contributor.authorPlaza-Díaz, Julio
dc.contributor.authorSolis-Urra, Patricio
dc.contributor.authorAragón-Vela, Jerónimo
dc.contributor.authorRodríguez-Rodríguez, Fernando
dc.contributor.authorOlivares-Arancibia, Jorge
dc.contributor.authorÁlvarez-Mercado, I.
dc.date.accessioned2022-10-21T19:42:34Z
dc.date.available2022-10-21T19:42:34Z
dc.date.issued2021-02
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is an increasing cause of chronic liver illness associated with obesity and metabolic disorders, such as hypertension, dyslipidemia, or type 2 diabetes mellitus. A more severe type of NAFLD, non-alcoholic steatohepatitis (NASH), is considered an ongoing global health threat and dramatically increases the risks of cirrhosis, liver failure, and hepatocellular carcinoma. Several reports have demonstrated that liver steatosis is associated with the elevation of certain clinical and biochemical markers but with low predictive potential. In addition, current imaging methods are inaccurate and inadequate for quantification of liver steatosis and do not distinguish clearly between the microvesicular and the macrovesicular types. On the other hand, an unhealthy status usually presents an altered gut microbiota, associated with the loss of its functions. Indeed, NAFLD pathophysiology has been linked to lower microbial diversity and a weakened intestinal barrier, exposing the host to bacterial components and stimulating pathways of immune defense and inflammation via toll-like receptor signaling. Moreover, this activation of inflammation in hepatocytes induces progression from simple steatosis to NASH. In the present review, we aim to: (a) summarize studies on both human and animals addressed to determine the impact of alterations in gut microbiota in NASH; (b) evaluate the potential role of such alterations as biomarkers for prognosis and diagnosis of this disorder; and (c) discuss the involvement of microbiota in the current treatment for NAFLD/NASH (i.e., bariatric surgery, physical exercise and lifestyle, diet, probiotics and prebiotics, and fecal microbiota transplantation). © 2021 by the authors. Licensee MDPI, Basel, Switzerland.es
dc.description.sponsorshipIndexación: Scopuses
dc.identifier.citationBiomedicines Open AccessVolume 9, Issue 2, Pages 1 - 21 February 2021 Article number 145es
dc.identifier.issn22279059
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/24404
dc.language.isoenes
dc.publisher22279059es
dc.subjectFecal microbiota transplantation; Intestinal permeability; Microbiota; Non-alcoholic steatohepatitis; Physical exercise; Probioticses
dc.titleInsights into the impact of microbiota in the treatment of nafld/nash and its potential as a biomarker for prognosis and diagnosises
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Julio Plaza-Díaz_Insights-into-the-impact-of-microbiota-in-the-treatment-of-nafldnash-and-its-potential-as-a-biomarker-for-prognosis-and-diagnosisBiomedicines.pdf
Tamaño:
635.68 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FEd - Artículos de Revista